GH1 and acromegaly: Pegvisomant is highly efficacious at attenuating hGHR activation and normalizing serum IGF1 levels in patients with elevated GH (62, 64) and is currently the only clinically approved GHR antagonist marketed worldwide to treat patients with acromegaly (2, 62).